Apollomics (APLM) Preferred Stock Liabilities (2021 - 2023)
Apollomics (APLM) posted quarterly Preferred Stock Liabilities of -$76.4 million for Q4 2023, up 59.7% year-over-year from -$47.9 million in Q4 2022, and up 59.7% quarter-over-quarter from -$189.6 million in Q4 2022.
Apollomics (APLM) Preferred Stock Liabilities (2021 - 2023) Analysis & Trends
Apollomics (APLM) has reported Preferred Stock Liabilities for 3 consecutive years, with -$76.4 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Preferred Stock Liabilities rose 59.7% year-over-year to -$76.4 million; the TTM figure through Dec 2023 stood at -$76.4 million (up 59.7% YoY), while the FY2023 annual figure was -$76.4 million, down 114.93% from the prior year.
- Preferred Stock Liabilities grew to -$76.4 million in Q4 2023 per APLM's latest filing, from -$189.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $23.7 million in Q2 2022 and bottomed at -$189.6 million in Q4 2022.
- Historically, Preferred Stock Liabilities has averaged -$70.0 million across 3 years, with a median of -$56.9 million in 2021.
- Annual changes were most pronounced in 2022 — Preferred Stock Liabilities slumped 406.75% — and 2023, when it jumped 59.7%.
- Apollomics' Preferred Stock Liabilities stood at -$37.4 million in 2021, then plunged by 406.75% to -$189.6 million in 2022, then surged by 59.7% to -$76.4 million in 2023.
- Business Quant data shows APLM's Preferred Stock Liabilities at -$76.4 million in Q4 2023, -$189.6 million in Q4 2022, and $23.7 million in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Apollomics | 35.18 Mn | 31.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -76.43 Mn |
| Dec 31, 2022 | -189.65 Mn |
| Jun 30, 2022 | 23.67 Mn |
| Dec 31, 2021 | -37.42 Mn |